Nanomedical innovation: The SEON-concept for an improved cancer therapy with magnetic nanoparticles

Nanomedicine

Volumn 10, Issue 21, 2015, Pages 3287-3304

  Lyer, Stefan ^a   Tietze, Rainer ^a   Unterweger, Harald ^a   Zaloga, Jan ^a   Singh, Raminder ^a   Matuszak, Jasmin ^a   Poettler, Marina ^a   Friedrich, Ralf P ^a   Duerr, Stephan ^a   Cicha, Iwona ^a   Janko, Christina ^a   Alexiou, Christoph ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Cancer; chemotherapy; drug delivery; imaging; iron oxide nanoparticles; magnetic drug targeting; nanomedicine; nanotechnology; oncology; SEON concept

Indexed keywords

DOXORUBICIN; MAGNETIC NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; NANOPARTICLE;

CANCER THERAPY; DRUG TARGETING; GOOD MANUFACTURING PRACTICE; HUMAN; HYDRODYNAMICS; MAGNETIC FIELD; NANOPHARMACEUTICS; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; TUMOR VASCULARIZATION; ZETA POTENTIAL; MAGNETISM; NEOPLASMS;

HUMANS; MAGNETICS; NANOPARTICLES; NEOPLASMS;

EID: 84944939650     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.159     Document Type: Review

References (107)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 49(6), 1374-1403 (2013).
2. Who. Globocan 2012: Estimated Cancer Incidence Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx
3. Langer T, Am Zehnhoff-Dinnesen A, Radtke S, Meitert J Zolk O. Understanding platinum-induced ototoxicity. Trends Pharmacol. Sci. 34(8), 458-469 (2013).
4. Khanna R, Anger C. Patterns of patients stopping their anti-cancer drug due to its associated side effects in France Germany, Italy, Spain and UK (EU5). Presented at: ESMO 2014. Madrid, Spain, 26-30 September 2014 (Abstract 1551P).
5. Freeman MW, Arrott A, Watson JHL. Magnetism in medicine. J. Appl. Phys. 31(5), S404-S405 (1960).
6. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26(18), 3995-4021 (2005).
7. Amstad E, Textor M, Reimhult E. Stabilization and functionalization of iron oxide nanoparticles for biomedical applications. Nanoscale 3(7), 2819-2843 (2011).
8. Laurent S, Saei AA, Behzadi S, Panahifar A, Mahmoudi M. Superparamagnetic iron oxide nanoparticles for delivery of therapeutic agents: opportunities and challenges. Expert Opin. Drug Deliv. 11(9), 1449-1470 (2014).
9. Alexiou C, Jurgons R, Schmid RJ et al. Magnetic drug targeting: biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. J. Drug Target. 11(3), 139-149 (2003).
10. Pelgrift RY, Friedman AJ. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv. Drug Deliv. Rev. 65(13-14), 1803-1815 (2013).
11. Bunjes H. Lipid nanoparticles for the delivery of poorly water-soluble drugs. J. Pharm. Pharmacol. 62(11), 1637-1645 (2010).
12. Li R, Lim S-J, Choi H-G, Lee M-K. Solid lipid nanoparticles as drug delivery system for water-insoluble drugs. J. Pharm. Invest. 40, 63-73 (2010).
13. Usha YN, Angel TT, Udupa N. Nanotechnology: perspectives on solubility/bioavailability enhancement. Pharma Rev. 8(45), 59-66 (2010).
14. Pankhurst QA, Thanh NKT, Jones SK, Dobson J. Progress in applications of magnetic nanoparticles in biomedicine. J. Phys. D Appl. Phys. 42(22), 224001 (2009).
15. Storm G, Belliot SO, Daemen T, Lasic DD. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug Deliv. Rev. 17(1) 31-48 (1995).
16. Brigger I, Morizet J, Laudani L et al. Negative preclinical results with stealth((R)) nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model. J. Control. Release 100(1), 29-40 (2004).
17. Bilkenroth U, Taubert H, Riemann D, Rebmann U Heynemann H, Meye A. Detection and enrichment of disseminated renal carcinoma cells from peripheral blood by immunomagnetic cell separation. Int. J. Cancer 92(4) 577-582 (2001).
18. Taupitz M, Wagner S, Hamm B, Dienemann D, Lawaczeck R, Wolf K. J. MR Lymphography using iron oxide particles. Detection of lymph node metastases in the VX2 rabbit tumour model. Acta Radiol. 34 10-15 (1993).
19. Harisinghani MG, Barentsz J, Hahn PF et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 348(25), 2491-2499 (2003).
20. Gaglia JL, Harisinghani M, Aganj I et al. Noninvasive mapping of pancreatic inflammation in recent-onset Type-1 diabetes patients. Proc. Natl Acad. Sci. USA 112(7) 2139-2144 (2015).
21. Alexiou C, Arnold W, Klein RJ et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res. 60(23) 6641-6648 (2000).
22. Pankhurst QA, Connolly J, Jones SK, Dobson J. Applications of magnetic nanoparticles in biomedicine. J. Phys. D Appl. Phys. 36(13), R167-R181 (2003).
23. Lyer S, Schreiber E, Tietze R et al. Nanotechnology and cancer treatment: magnetic nanoparticles for a new and innovative drug delivery system. Anticancer Res. 31(5) 1991-1992 (2011).
24. Tietze R, Lyer S, Durr S et al. Efficient drug-delivery using magnetic nanoparticles-biodistribution and therapeutic effects in tumour bearing rabbits. Nanomed. Nanotechnol. 9(7), 961-971 (2013).
25. Alexiou C. Target tumor therapy with "magnetic drug targeting": therapeutic efficacy and biokinetic study of ferrofluid bound mitoxantrone. Clin. Cancer Res. 7(11) s3704-s3705 (2001).
26. Polyak B, Friedman G. Magnetic targeting for site-specific drug delivery: applications and clinical potential. Expert Opin. Drug Deliv. 6(1), 53-70 (2009).
27. Widder KJ, Senyei AE, Ranney DF. Magnetically responsive microspheres and other carriers for the biophysical targeting of antitumor agents. Adv. Pharmacol. Chemother. 16 213-271 (1979).
28. Widder KJ, Morris RM, Poore GA, Howard DP, Senyei AE. Selective targeting of magnetic albumin microspheres containing low-dose doxorubicin: total remission in Yoshida sarcoma-bearing rats. Eur. J. Cancer Clin. Oncol. 19(1) 135-139 (1983).
29. Lubbe AS, Bergemann C, Huhnt W et al. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res. 56(20), 4694-4701 (1996).
30. Lubbe AS, Bergemann C, Riess H et al. Clinical experiences with magnetic drug targeting: a phase I study with 4-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res. 56(20), 4686-4693 (1996).
31. Alexiou C, Arnold W, Klein RJ et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res 60(23) 6641-6648 (2000).
32. Alexiou C, Diehl D, Henninger P et al. A high field gradient magnet for magnetic drug targeting. IEEE Trans. Appl. Supercond. 16(2), 1527-1530 (2006).
33. Agency EM. Guideline on the requirements to the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials. EMEA 03/2006 (Directive CHMP/QWP/185401/2004 final). http://ec.europa.eu/health/files/eudralex
34. Agency EM. Directive EMEA/CHMP/79769/2006: Reflection paper on nanotechnology-based medicinal products for human use, (EMEA 06/2006). www.ema.europa.eu/docs/en-GB/document-library
35. Agency EM. Directive EMA/484400/2014: Mandate of the EMA Innovation Task force (ITF). (08/2014). www.ema.europa.eu/docs/en-GB/document-library
36. Laurent S, Forge D, Port M et al. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization physicochemical characterizations, and biological applications. Chem. Rev. 108(6), 2064-2110 (2008).
37. Yu WW, Falkner JC, Yavuz CT, Colvin VL. Synthesis of monodisperse iron oxide nanocrystals by thermal decomposition of iron carboxylate salts. Chem. Commun. (Camb.) (20), 2306-2307 (2004).
38. Xie J, Wang J, Niu G et al. Human serum albumin coated iron oxide nanoparticles for efficient cell labeling. Chem. Commun. (Camb.) 46(3), 433-435 (2010).
39. Gonzales M, Mitsumori LM, Kushleika JV, Rosenfeld ME Krishnan KM. Cytotoxicity of iron oxide nanoparticles made from the thermal decomposition of organometallics and aqueous phase transfer with Pluronic F127. Contrast Media Mol. Imaging 5(5), 286-293 (2010).
40. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng. 14 1-16 (2012).
41. Mahmoudi M, Saeedi-Eslami SN, Shokrgozar MA et al. Cell "vision": complementary factor of protein corona in nanotoxicology. Nanoscale 4(17), 5461-5468 (2012).
42. Gebauer JS, Malissek M, Simon S et al. Impact of the nanoparticle-protein corona on colloidal stability and protein structure. Langmuir 28(25), 9673-9679 (2012).
43. Unterweger H, Tietze R, Janko C et al. Development and characterization of magnetic iron oxide nanoparticles with a cisplatin-bearing polymer coating for targeted drug delivery. Int. J. Nanomedicine 9 3659-3676 (2014).
44. Kamat M, El-Boubbou K, Zhu DC et al. Hyaluronic acid immobilized magnetic nanoparticles for active targeting and imaging of macrophages. Bioconj. Chem. 21(11), 2128-2135 (2010).
45. Zaloga J, Janko C, Nowak J et al. Development of a lauric acid/albumin hybrid iron oxide nanoparticle system with improved biocompatibility. Int. J. Nanomedicine 9, 4847-4866 (2014).
46. Bica D, Vekas L, Avdeev MV et al. Sterically stabilized water based magnetic fluids: synthesis, structure and properties. J. Magn. Magn. Mater. 311(1), 17-21 (2007).
47. Laurent S, Dutz S, Hafeli UO, Mahmoudi M. Magnetic fluid hyperthermia: focus on superparamagnetic iron oxide nanoparticles. Adv. Colloid Interface Sci. 166(1-2), 8-23 (2011).
48. Colvin VL. The potential environmental impact of engineered nanomaterials. Nat. Biotechnol. 21(10) 1166-1170 (2003).
49. Banerjee R, Katsenovich Y, Lagos L, Mciintosh M, Zhang X, Li CZ. Nanomedicine: magnetic nanoparticles and their biomedical applications. Curr. Med. Chem. 17(27) 3120-3141 (2010).
50. Reddy LH, Arias JL, Nicolas J, Couvreur P. Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem. Rev. 112(11), 5818-5878 (2012).
51. Tombácz E, Tóth IY, Nesztor D et al. Adsorption of organic acids on magnetite nanoparticles, pH-dependent colloidal stability and salt tolerance. Colloids Surf. Physicochem. Eng. Aspects 435(0), 91-96 (2013).
52. Angelova A, Angelov B, Garamus VM, Couvreur P, Lesieur S. Small-angle X-ray scattering investigations of biomolecular confinement, loading, and release from liquid-crystalline nanochannel assemblies. J. Phys. Chem. Lett. 3(3), 445-457 (2012).
53. Nowak J, Wiekhorst F, Trahms L, Odenbach S. The influence of hydrodynamic diameter and core composition on the magnetoviscous effect of biocompatible ferrofluids. J. Phys. Condes. Matter 26(17), 7 (2014).
54. Eberbeck D, Lange A, Hentschel M. Identification of aggregates of magnetic nanoparticles in ferrofluids at low concentrations. J. Appl. Crystallogr. 36 1069-1074 (2003).
55. Jurgons R, Seliger C, Hilpert A, Trahms L, Odenbach S Alexiou C. Drug loaded magnetic nanoparticles for cancer therapy. J. Phys. Condens. Matter 18(38), S2893-S2902 (2006).
56. Wiekhorst F, Seliger C, Jurgons R et al. Quantification of magnetic nanoparticles by magnetorelaxometry and comparison to histology after magnetic drug targeting. J. Nanosci. Nanotechnol. 6(9-10), 3222-3225 (2006).
57. Wiekhorst F, Liebl M, Steinhoff U, Trahms L, Lyer S, Duerr S, Alexiou C. Magnetorelacometry for in-vivo quantification of magnetic nanoparticle distributions after magnetic drug tarbeting in a rabbit carcinoma model. Presented at: 2nd International Workshop on Magnetic Particle Imaging IWMPI 2012. Lübeck, Germany, 15-16 March 2012.
58. Richter H, Kettering M, Wiekhorst F, Steinhoff U, Hilger I, Trahms L. Magnetorelaxometry for localization and quantification of magnetic nanoparticles for thermal ablation studies. Phys. Med. Biol. 55(3), 623-633 (2010).
59. European Comission. Comission directive 2003/63/EC of the European Pariament and of the Concil on the Community code relating to medicinal products for human use. http://ec.europa.eu/health/documents/eudralex/vol-1
60. Zaloga J, Janko C, Agarwal R et al. Different storage conditions influence biocompatibility and physicochemical properties of iron oxide nanoparticles. Int. J. Mol. Sci. 16(5) 9368-9384 (2015).
61. Cherry EM, Maxim PG, Eaton JK. Particle size, magnetic field, and blood velocity effects on particle retention in magnetic drug targeting. Med. Phys. 37(1), 175-182 (2010).
62. Cherry EM, Eaton JK. A comprehensive model of magnetic particle motion during magnetic drug targeting. Int. J. Multiphase Flow 59, 173-185 (2014).
63. David AE, Cole AJ, Chertok B, Park YS, Yang VC. A combined theoretical and in vitro modeling approach for predicting the magnetic capture and retention of magnetic nanoparticles in vivo. J. Control. Release 152(1), 67-75 (2011).
64. Heidsieck A, Vosen S, Zimmermann K, Wenzel D, Gleich B. Analysis of Trajectories for Targeting of Magnetic Nanoparticles in Blood Vessels. Mol. Pharm. 9(7) 2029-2038 (2012).
65. Gitter K, Odenbach S. Quantitative targeting maps based on experimental investigations for a branched tube model in magnetic drug targeting. J. Magn. Magn. Mater. 323(23) 3038-3042 (2011).
66. Seliger C, Jurgons R, Wiekhorst F et al. In vitro investigation of the behaviour of magnetic particles by a circulating artery model. J. Magn. Magn. Mater. 311(1), 358-362 (2007).
67. Lyer S. TR, Jurgons R, Richter H, Wiekhorst F, Schwarz K Trahms L, Alexiou C. Distribution of magnetic nanoparticles after magnetic drug targetin in an ex vivo bovine artery model. Presented at: World Congress 2009. Munich 7-12 September 2009.
68. Richter H, Wiekhorst F, Schwarz K et al. Magnetorelaxometric quantification of magnetic nanoparticles in an artery model after ex vivo magnetic drug targeting. Phys. Med. Biol. 54(18), N417-N424 (2009).
69. Tietze R, Rahn H, Lyer S et al. Visualization of superparamagnetic nanoparticles in vascular tissue using X mu CT and histology. Histochem. Cell Biol. 135(2), 153-158 (2011).
70. Cicha I, Beronov K, Ramirez EL et al. Shear stress preconditioning modulates endothelial susceptibility to circulating TNF-alpha and monocytic cell recruitment in a simplified model of arterial bifurcations. Atherosclerosis 207(1), 93-102 (2009).
71. Matuszak J, Zaloga J, Friedrich RP et al. Endothelial biocompatibility and accumulation of SPION under flow conditions. J. Magn. Magn. Mater. 380, 20-26 (2015).
72. Haynes CL. The emerging field of nanotoxicology. Anal. Bioanal. Chem. 398(2), 587-588 (2010).
73. Paasonen L, Laaksonen T, Johans C, Yliperttula M, Kontturi K, Urtti A. Gold nanoparticles enable selective light-induced contents release from liposomes. J. Control. Release 122(1) 86-93 (2007).
74. Wickstrom SA, Lange A, Hess MW et al. Integrin-linked kinase controls microtubule dynamics required for plasma membrane targeting of caveolae. Dev. Cell 19(4), 574-588 (2010).
75. Andes D, Diekema DJ, Pfaller MA, Bohrmuller J, Marchillo K, Lepak A. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob. Agents Chemother. 54(6), 2497-2506 (2010).
76. Hristozov DR, Gottardo S, Critto A, Marcomini A. Risk assessment of engineered nanomaterials: a review of available data and approaches from a regulatory perspective. Nanotoxicology 6, 880-898 (2012).
77. Hirsch C, Roesslein M, Krug HF, Wick P. Nanomaterial cell interactions: are current in vitro tests reliable Nanomedicine (Lond.) 6(5), 837-847 (2011).
78. Davoren M, Herzog E, Casey A et al. In vitro toxicity evaluation of single walled carbon nanotubes on human A549 lung cells. Toxicol. In Vitro 21(3), 438-448 (2007).
79. Monteiro-Riviere NA, Inman AO, Zhang LW. Limitations and relative utility of screening assays to assess engineered nanoparticle toxicity in a human cell line. Toxicol. Appl. Pharmacol. 234(2), 222-235 (2009).
80. Hoskins C, Cuschieri A, Wang L. The cytotoxicity of polycationic iron oxide nanoparticles: common endpoint assays and alternative approaches for improved understanding of cellular response mechanism. J. Nanobiotechnol. 10, 15 (2012).
81. Garcia SN, Gutierrez L, Mcnulty A. Real-Time cellular analysis as a novel approach for in vitro cytotoxicity testing of medical device extracts. J. Biomed. Mater. Res. A 101(7) 2097-2106 (2013).
82. Durr S, Janko C, Lyer S et al. Magnetic nanoparticles for cancer therapy. Nanotechnol. Rev. 2(4), 395-409 (2013).
83. Durr S, Lyer S, Mann J et al. Real-Time cell analysis of human cancer cell lines after chemotherapy with functionalized magnetic nanoparticles. Anticancer Res. 32(5) 1983-1989 (2012).
84. Janko C, Durr S, Munoz LE et al. Magnetic drug targeting reduces the chemotherapeutic burden on circulating leukocytes. Int. J. Mol. Sci. 14(4), 7341-7355 (2013).
85. Friedrich RJ C, Pöttler M, Tripal P, Zaloga J, Nowak J Odenbach S, Liebl M, Trahms L, Stapf M, Hilger I, Lyer S, Alexiou C. Flow cytometry for intracellular SPION quantification: specificity and sensitivity in comparison with spectroscopic methods. Int. J. Nanomedicine 10, 4185-4201 (2015).
86. Hoehn M, Kustermann E, Blunk J et al. Monitoring of implanted stem cell migration in vivo: a highly resolved in vivo magnetic resonance imaging investigation of experimental stroke in rat. Proc. Natl Acad. Sci. USA 99(25) 16267-16272 (2002).
87. Foroutan F, Jokerst JV, Gambhir SS, Vermesh O, Kim HW, Knowles JC. Sol-gel synthesis and electrospraying of biodegradable (P2O5)55-(CaO)30-(Na2O)15 glass nanospheres as a transient contrast agent for ultrasound stem cell imaging. ACS Nano 9(2), 1868-1877 (2015).
88. Morimoto Y, Okumura M, Sugibayashi K, Kato Y. Biomedical applications of magnetic fluids II. 1) preparation and magnetic guidance of magnetic albumin microsphere for site specific drug delivery in vivo. J. Pharmacobiodyn. 4(8) 624-631 (1981).
89. Osato T, Ito Y. In vitro cultivation and immunofluorescent studies of transplantable carcinomas Vx2 and Vx7. Persistence of a Shope virus-related antigenic substance in the cells of both tumors. J. Exp. Med. 126(5), 881-886 (1967).
90. Shope RE, Hurst EW. Infectious papillomatosis of rabbits: with a note on the histopathology. J. Exp. Med. 58(5) 607-624 (1933).
91. Zheng LF, Li YJ, Wang H et al. Combination of vascular endothelial growth factor antisense oligonucleotide therapy and radiotherapy increases the curative effects against maxillofacial VX2 tumors in rabbits. Eur. J. Radiol. 78(2) 272-276 (2011).
92. Mast TD, Barthe PG, Makin IRS et al. Treatment of rabbit liver cancer in vivo using miniaturized image-ablate ultrasound arrays. Ultrasound Med. Biol. 37(10), 1609-1621 (2011).
93. Bruners P, Braunschweig T, Hodenius M et al. Thermoablation of malignant kidney tumors using magnetic nanoparticles: an in vivo feasibility study in a rabbit model. Cardiovasc. Intervent. Radiol. 33(1), 127-134 (2010).
94. Lyer S, Tietze R, Jurgons R et al. Visualisation of tumour regression after local chemotherapy with magnetic nanoparticles-a pilot study. Anticancer Res. 30(5) 1553-1557 (2010).
95. Alexiou C, Arnold W, Hulin P et al. Magnetic mitoxantrone nanoparticle detection by histology, X-ray and MRI after magnetic tumor targeting. J. Magn. Magn. Mater. 225(1-2) 187-193 (2001).
96. Alexiou C, Jurgons R, Schmid R et al. [Magnetic Drug Targeting-a new approach in locoregional tumor therapy with chemotherapeutic agents. Experimental animal studies]. HNO 53(7), 618-622 (2005).
97. Alexiou C, Jurgons R, Schmid R et al. In vitro and in vivo investigations of targeted chemotherapy with magnetic nanoparticles. J. Magn. Magn. Mater. 293(1), 389-393 (2005).
98. Alexiou C, Jurgons R, Seliger C, Iro H. Medical applications of magnetic nanoparticles. J. Nanosci. Nanotechnol. 6(9-10) 2762-2768 (2006).
99. Alexiou C, Jurgons R, Seliger C, Brunke O, Iro H Odenbach S. Delivery of superparamagnetic nanoparticles for local chemotherapy after intraarterial infusion and magnetic drug targeting. Anticancer Res. 27(4A), 2019-2022 (2007).
100. Rahn H, Alexiou C, Trahms L, Odenbach S. 3-Dimensional quantitative detection of nanoparticle content in biological tissue samples after local cancer treatment. J. Magn. Magn. Mater. 360 92-97 (2014).
101. Rahn H, Gomez-Morilla I, Jurgons R, Alexiou C, Odenbach S. Microcomputed tomography analysis of ferrofluids used for cancer treatment. J. Phys. Condens. Matter 20(20) 204152 (2008).
102. Tietze R, Schreiber E, Lyer S, Alexiou C. Mitoxantrone loaded superparamagnetic nanoparticles for drug targeting: a versatile and sensitive method for quantification of drug enrichment in rabbit tissues using HPLC-UV. J. Biomed. Biotechnol. 2010 597304 (2010).
103. Cicha I, Garlichs Christoph D, Alexiou C. Cardiovascular therapy through nanotechnology-how far are we still from bedside Eur. J. Nanomed. 6(2), 63 (2014).
104. Durr S, Bohr C, Pottler M et al. Magnetic Tissue engineering for voice rehabilitation-first steps in a promising field. Anticancer Res. 34(11), 6806-6806 (2014).
105. Lyer S, Janko C, Tietze R et al. Hyperthermia in targeted tumour therapy using magnetic nanoparticles-first results. Anticancer Res. 34(11), 6835-6836 (2014).
106. Durr S, Schmidt W, Janko C et al. A novel magnetic field device for inducing hyperthermia using magnetic nanoparticles. Biomed. Tech (Berl.) doi:10.1515/bmt-2013-4129 (2013) (Epub ahead of print).
107. Unterweger H, Tietze R, Taccardi N et al. Boron containing magnetic nanoparticles for neutron capture therapy-an innovative approach for specifically targeting tumors. Anticancer Res. 34(11), 6848-6849 (2014).